Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer
about
Putting a bit into the polo-box domain of polo-like kinase 1DNA methylation changes in epithelial ovarian cancer histotypes.Identification of Polo-like kinase 1 interaction inhibitors using a novel cell-based assayIntegrative modeling of multi-omics data to identify cancer drivers and infer patient-specific gene activityRas/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer TreatmentProtein kinase A type II-α regulatory subunit regulates the response of prostate cancer cells to taxane treatment.Broad H3K4me3 is associated with increased transcription elongation and enhancer activity at tumor-suppressor genes.MicroRNA-27b up-regulated by human papillomavirus 16 E7 promotes proliferation and suppresses apoptosis by targeting polo-like kinase2 in cervical cancer.Polo-like kinase 2 is a mediator of hedgehog survival signaling in cholangiocarcinoma.Mechanisms and therapeutic potential of inhibiting drug efflux transporters.Polo-like kinase 3 is associated with improved overall survival in cholangiocarcinoma.p53-Dependent and cell specific epigenetic regulation of the polo-like kinases under oxidative stress.
P2860
Q26779135-5859FAAB-E38B-49F5-AC33-E180DC2EA226Q27690722-9F533970-9267-495F-9907-1ABF26D9E231Q28820936-0C8F5DF1-BCB7-406C-9C01-D5885EB1B733Q31044138-4784965D-7FBC-4A24-A74D-7469E9202E8BQ34307356-50A8A6AB-454D-48AC-A719-210B704A70F1Q35801683-0EEB1162-AF51-4ABD-B9E9-529756630CA7Q36188433-E139C1EF-4D03-4BC1-947A-BEC3997FD9FEQ36659374-B7B39FF8-D59D-4D3E-B221-9A87B85F3FE4Q37190143-AC2E4D0C-2161-4633-BF96-2D01437105BCQ37262757-14D74808-176C-4451-8B75-B93A25FD697CQ38388828-BE5F2AAF-4C3E-4860-BF5C-531DFC1979D7Q38893743-29E151FC-A115-4D2D-B6E3-D17379893A7DQ39027006-60148CBA-D010-4DE4-BA76-F4D870EEC202
P2860
Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Polo Like Kinase 2 Tumour Supp ...... y/resistance in ovarian cancer
@ast
Polo Like Kinase 2 Tumour Supp ...... y/resistance in ovarian cancer
@en
Polo Like Kinase 2 Tumour Supp ...... y/resistance in ovarian cancer
@nl
type
label
Polo Like Kinase 2 Tumour Supp ...... y/resistance in ovarian cancer
@ast
Polo Like Kinase 2 Tumour Supp ...... y/resistance in ovarian cancer
@en
Polo Like Kinase 2 Tumour Supp ...... y/resistance in ovarian cancer
@nl
prefLabel
Polo Like Kinase 2 Tumour Supp ...... y/resistance in ovarian cancer
@ast
Polo Like Kinase 2 Tumour Supp ...... y/resistance in ovarian cancer
@en
Polo Like Kinase 2 Tumour Supp ...... y/resistance in ovarian cancer
@nl
P2093
P2860
P921
P356
P1433
P1476
Polo Like Kinase 2 Tumour Supp ...... y/resistance in ovarian cancer
@en
P2093
Alastair Thompson
Eleftheria Hatzimichael
Helen M Coley
Nelofer Syed
Sarah Blagden
P2860
P356
10.18632/ONCOTARGET.332
P407
P5008
P577
2012-01-01T00:00:00Z